Medicine pack check sheet

Source-linked reading points

• 150 mg describes total content of this exact single-dose lyophilised-powder vial; it is not an individual treatment amount, a self-calculated diluent volume or product that may be saved/shared. The label's reconstitution, dilution, infusion, storage and disposal steps are sterile medication operations for the treating facility and should not be recreated at home from a webpage.
• This is an intravenous HERCEPTIN label and has different administration instructions from subcutaneous trastuzumab products; it also states that it must not be substituted for or with ado-trastuzumab emtansine or fam-trastuzumab deruxtecan. Shared trastuzumab wording, HER2 terminology or similar packages do not support self-switching, combining, catch-up use or changing a course.
• The label warns about cardiomyopathy, infusion reactions, pulmonary toxicity and embryo-fetal risk. With breathing difficulty, chest symptoms, marked low-blood-pressure-like illness, fever/chills, persistent cough, unusual fatigue, swelling or another acute concern, contact the oncology team promptly or use local urgent medical support; do not self-pause or restart infusions from a webpage.
• HER2 overexpression, gene amplification or a test result are conditions interpreted together by authorised testing and specialist teams in specific disease settings, not a basis for self-deciding on HERCEPTIN from one test name or value. Pathology, method, tumour type, cardiac function, prior treatment and the current target-market label must be reviewed together.